Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

NCT04916860 is registered in ClinicalTrials.gov with Hebei Senlang Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT04916860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04916860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Lead sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
January 27, 2021
Completion date
March 31, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

senl-t7 car t cells for cd7+ t-cell lymphoblastic leukemia or t-cell lymphoblastic lymphoma